BioCardia, Inc.
BCDA Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$0.92
KIRA · Stoqly’s AI analyst, in plain words
- BioCardia, Inc. had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.
- BioCardia, Inc. lost $8.2M in fiscal 2025.
- Free cash flow was −$7.4M in fiscal 2025, — of revenue.
Market cap
—
P/E
—
Revenue
$0.0M
Net income
−$8.2M
Free cash flow
−$7.4M
Operating margin
—
BioCardia, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−100.0%
No. Sales fell 100.0% last year.
Does it make a profit?
−$8.2M
No. It lost money last year.
What BioCardia, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 24, 2026
- Legal name
- BioCardia, Inc.
- CIK
- 0000925741
BioCardia, Inc. · BCDA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.0M | $1.4M | $0.5M | $0.1M | $0.0M |
| Revenue growth | 600.0% | 33.2% | −64.7% | −87.8% | −100.0% |
| Gross margin | 100.0% | — | — | — | — |
| Operating margin | −1,244.3% | −880.3% | −2,441.1% | −13,794.8% | — |
| Net income | −$12.6M | −$11.9M | −$11.6M | −$7.9M | −$8.2M |
| Net margin | −1,243.6% | −880.7% | −2,425.8% | −13,700.0% | — |
| Diluted EPS | −$0.75 | — | — | — | — |
| Cash | |||||
| Cash from operations | −$10.4M | −$10.6M | −$10.0M | −$7.9M | −$7.4M |
| Capital expenditure | $0.1M | $0.1M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$10.5M | −$10.6M | −$10.0M | −$7.9M | −$7.4M |
| FCF margin | −1,032.7% | −786.3% | −2,093.5% | −13,606.9% | — |
| Share count change | 67.2% | — | — | — | — |
| Debt and strength | |||||
| Cash and short-term investments | $12.9M | $7.4M | $1.1M | $2.4M | $2.5M |
| Shareholders' equity | $10.4M | $4.9M | −$1.6M | $0.8M | $0.9M |
| Current ratio | 3.6x | 2.2x | 0.4x | 1.1x | 1.1x |
| Returns and quality | |||||
| Return on equity | −85.4% | −156.0% | −703.6% | — | −950.1% |
| Return on tangible equity | −121.7% | −243.4% | — | −949.3% | −919.3% |
| Piotroski F-score | 3 | — | — | — | — |
| Altman Z'' | −26.0 | −51.1 | −197.4 | −153.8 | −176.2 |
Insiders bought, 12 months
$0.2M
2 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
BioCardia, Inc. · BCDA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.92 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0000925741). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.